急性間欠性ポルフィリン症の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Acute Intermittent Porphyria Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-14627 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、101ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、急性間欠性ポルフィリン症の世界市場を広く調査・分析し、今後の市場展望をまとめております。急性間欠性ポルフィリン症の種類別市場規模（ゴナドトロピン放出ホルモン類似体、予防的ヘマチン点滴）、用途別市場規模（病院、診療所、研究センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Dahaner、Siemens、Roche、ACON Laboratories、Bio-Rad Laboratories、Sysmex Corporation、ARKRAY ・地域別グローバル市場分析 2015年-2020年 ・急性間欠性ポルフィリン症の北米市場（アメリカ、カナダ、メキシコ） ・急性間欠性ポルフィリン症のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・急性間欠性ポルフィリン症のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・急性間欠性ポルフィリン症の南米市場（ブラジル、アルゼンチン） ・急性間欠性ポルフィリン症の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ゴナドトロピン放出ホルモン類似体、予防的ヘマチン点滴 ・用途別分析：病院、診療所、研究センター ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Acute Intermittent Porphyria market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Acute Intermittent Porphyria market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Acute Intermittent Porphyria market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Acute Intermittent Porphyria market has been segmented into:
Gonadotropin-Releasing Hormone Analogues
Prophylactic Hematin Infusions

By Application, Acute Intermittent Porphyria has been segmented into:
Hospitals & Clinics
Research Centers

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Acute Intermittent Porphyria market presented in the report. This section sheds light on the sales growth of different regional and country-level Acute Intermittent Porphyria markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Acute Intermittent Porphyria market.

The report offers in-depth assessment of the growth and other aspects of the Acute Intermittent Porphyria market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Acute Intermittent Porphyria Market Share Analysis
Acute Intermittent Porphyria competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Acute Intermittent Porphyria sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Acute Intermittent Porphyria sales, revenue and market share for each player covered in this report.

The major players covered in Acute Intermittent Porphyria are:
Dahaner
Siemens
Roche
ACON Laboratories
Bio-Rad Laboratories
Sysmex Corporation
ARKRAY

レポート目次

---

Table of Contents

1 Acute Intermittent Porphyria Market Overview
1.1 Product Overview and Scope of Acute Intermittent Porphyria
1.2 Classification of Acute Intermittent Porphyria by Type
1.2.1 Global Acute Intermittent Porphyria Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Acute Intermittent Porphyria Revenue Market Share by Type in 2019
1.2.3 Gonadotropin-Releasing Hormone Analogues
1.2.4 Prophylactic Hematin Infusions
1.3 Global Acute Intermittent Porphyria Market by Application
1.3.1 Overview: Global Acute Intermittent Porphyria Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals & Clinics
1.3.3 Research Centers
1.4 Global Acute Intermittent Porphyria Market by Regions
1.4.1 Global Acute Intermittent Porphyria Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Acute Intermittent Porphyria (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Acute Intermittent Porphyria Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Acute Intermittent Porphyria Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Acute Intermittent Porphyria Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Acute Intermittent Porphyria Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Acute Intermittent Porphyria Status and Prospect (2015-2025)
2 Company Profiles
2.1 Dahaner
2.1.1 Dahaner Details
2.1.2 Dahaner Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Dahaner SWOT Analysis
2.1.4 Dahaner Product and Services
2.1.5 Dahaner Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
2.2 Siemens
2.2.1 Siemens Details
2.2.2 Siemens Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Siemens SWOT Analysis
2.2.4 Siemens Product and Services
2.2.5 Siemens Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Roche SWOT Analysis
2.3.4 Roche Product and Services
2.3.5 Roche Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
2.4 ACON Laboratories
2.4.1 ACON Laboratories Details
2.4.2 ACON Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 ACON Laboratories SWOT Analysis
2.4.4 ACON Laboratories Product and Services
2.4.5 ACON Laboratories Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
2.5 Bio-Rad Laboratories
2.5.1 Bio-Rad Laboratories Details
2.5.2 Bio-Rad Laboratories Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Bio-Rad Laboratories SWOT Analysis
2.5.4 Bio-Rad Laboratories Product and Services
2.5.5 Bio-Rad Laboratories Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
2.6 Sysmex Corporation
2.6.1 Sysmex Corporation Details
2.6.2 Sysmex Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Sysmex Corporation SWOT Analysis
2.6.4 Sysmex Corporation Product and Services
2.6.5 Sysmex Corporation Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
2.7 ARKRAY
2.7.1 ARKRAY Details
2.7.2 ARKRAY Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 ARKRAY SWOT Analysis
2.7.4 ARKRAY Product and Services
2.7.5 ARKRAY Acute Intermittent Porphyria Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Acute Intermittent Porphyria Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Acute Intermittent Porphyria Players Market Share
3.2.2 Top 10 Acute Intermittent Porphyria Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Acute Intermittent Porphyria Revenue and Market Share by Regions
4.2 North America Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
4.3 Europe Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
4.5 South America Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
5 North America Acute Intermittent Porphyria Revenue by Countries
5.1 North America Acute Intermittent Porphyria Revenue by Countries (2015-2020)
5.2 USA Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
5.3 Canada Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
5.4 Mexico Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
6 Europe Acute Intermittent Porphyria Revenue by Countries
6.1 Europe Acute Intermittent Porphyria Revenue by Countries (2015-2020)
6.2 Germany Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
6.3 UK Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
6.4 France Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
6.5 Russia Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
6.6 Italy Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Acute Intermittent Porphyria Revenue by Countries
7.1 Asia-Pacific Acute Intermittent Porphyria Revenue by Countries (2015-2020)
7.2 China Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
7.3 Japan Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
7.4 Korea Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
7.5 India Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
8 South America Acute Intermittent Porphyria Revenue by Countries
8.1 South America Acute Intermittent Porphyria Revenue by Countries (2015-2020)
8.2 Brazil Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
8.3 Argentina Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Acute Intermittent Porphyria by Countries
9.1 Middle East & Africa Acute Intermittent Porphyria Revenue by Countries (2015-2020)
9.2 Saudi Arabia Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
9.3 UAE Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
9.4 Egypt Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
9.5 South Africa Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Acute Intermittent Porphyria Revenue and Market Share by Type (2015-2020)
10.2 Global Acute Intermittent Porphyria Market Forecast by Type (2019-2024)
10.3 Gonadotropin-Releasing Hormone Analogues Revenue Growth Rate (2015-2025)
10.4 Prophylactic Hematin Infusions Revenue Growth Rate (2015-2025)
11 Global Acute Intermittent Porphyria Market Segment by Application
11.1 Global Acute Intermittent Porphyria Revenue Market Share by Application (2015-2020)
11.2 Acute Intermittent Porphyria Market Forecast by Application (2019-2024)
11.3 Hospitals & Clinics Revenue Growth (2015-2020)
11.4 Research Centers Revenue Growth (2015-2020)
12 Global Acute Intermittent Porphyria Market Size Forecast (2021-2025)
12.1 Global Acute Intermittent Porphyria Market Size Forecast (2021-2025)
12.2 Global Acute Intermittent Porphyria Market Forecast by Regions (2021-2025)
12.3 North America Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
12.4 Europe Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
12.6 South America Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Acute Intermittent Porphyria Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Acute Intermittent Porphyria by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Acute Intermittent Porphyria Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Acute Intermittent Porphyria Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Dahaner Corporate Information, Location and Competitors
Table 6. Dahaner Acute Intermittent Porphyria Major Business
Table 7. Dahaner Acute Intermittent Porphyria Total Revenue (USD Million) (2017-2018)
Table 8. Dahaner SWOT Analysis
Table 9. Dahaner Acute Intermittent Porphyria Product and Solutions
Table 10. Dahaner Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Siemens Corporate Information, Location and Competitors
Table 12. Siemens Acute Intermittent Porphyria Major Business
Table 13. Siemens Acute Intermittent Porphyria Total Revenue (USD Million) (2018-2019)
Table 14. Siemens SWOT Analysis
Table 15. Siemens Acute Intermittent Porphyria Product and Solutions
Table 16. Siemens Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Roche Corporate Information, Location and Competitors
Table 18. Roche Acute Intermittent Porphyria Major Business
Table 19. Roche Acute Intermittent Porphyria Total Revenue (USD Million) (2017-2018)
Table 20. Roche SWOT Analysis
Table 21. Roche Acute Intermittent Porphyria Product and Solutions
Table 22. Roche Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. ACON Laboratories Corporate Information, Location and Competitors
Table 24. ACON Laboratories Acute Intermittent Porphyria Major Business
Table 25. ACON Laboratories Acute Intermittent Porphyria Total Revenue (USD Million) (2017-2018)
Table 26. ACON Laboratories SWOT Analysis
Table 27. ACON Laboratories Acute Intermittent Porphyria Product and Solutions
Table 28. ACON Laboratories Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Bio-Rad Laboratories Corporate Information, Location and Competitors
Table 30. Bio-Rad Laboratories Acute Intermittent Porphyria Major Business
Table 31. Bio-Rad Laboratories Acute Intermittent Porphyria Total Revenue (USD Million) (2017-2018)
Table 32. Bio-Rad Laboratories SWOT Analysis
Table 33. Bio-Rad Laboratories Acute Intermittent Porphyria Product and Solutions
Table 34. Bio-Rad Laboratories Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Sysmex Corporation Corporate Information, Location and Competitors
Table 36. Sysmex Corporation Acute Intermittent Porphyria Major Business
Table 37. Sysmex Corporation Acute Intermittent Porphyria Total Revenue (USD Million) (2017-2018)
Table 38. Sysmex Corporation SWOT Analysis
Table 39. Sysmex Corporation Acute Intermittent Porphyria Product and Solutions
Table 40. Sysmex Corporation Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. ARKRAY Corporate Information, Location and Competitors
Table 42. ARKRAY Acute Intermittent Porphyria Major Business
Table 43. ARKRAY Acute Intermittent Porphyria Total Revenue (USD Million) (2017-2018)
Table 44. ARKRAY SWOT Analysis
Table 45. ARKRAY Acute Intermittent Porphyria Product and Solutions
Table 46. ARKRAY Acute Intermittent Porphyria Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Global Acute Intermittent Porphyria Revenue (Million USD) by Players (2015-2020)
Table 48. Global Acute Intermittent Porphyria Revenue Share by Players (2015-2020)
Table 49. Global Acute Intermittent Porphyria Revenue (Million USD) by Regions (2015-2020)
Table 50. Global Acute Intermittent Porphyria Revenue Market Share by Regions (2015-2020)
Table 51. North America Acute Intermittent Porphyria Revenue by Countries (2015-2020)
Table 52. North America Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Table 53. Europe Acute Intermittent Porphyria Revenue (Million USD) by Countries (2015-2020)
Table 54. Asia-Pacific Acute Intermittent Porphyria Revenue (Million USD) by Countries (2015-2020)
Table 55. South America Acute Intermittent Porphyria Revenue by Countries (2015-2020)
Table 56. South America Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Table 57. Middle East and Africa Acute Intermittent Porphyria Revenue (Million USD) by Countries (2015-2020)
Table 58. Middle East and Africa Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Table 59. Global Acute Intermittent Porphyria Revenue (Million USD) by Type (2015-2020)
Table 60. Global Acute Intermittent Porphyria Revenue Share by Type (2015-2020)
Table 61. Global Acute Intermittent Porphyria Revenue Forecast by Type (2021-2025)
Table 62. Global Acute Intermittent Porphyria Revenue by Application (2015-2020)
Table 63. Global Acute Intermittent Porphyria Revenue Share by Application (2015-2020)
Table 64. Global Acute Intermittent Porphyria Revenue Forecast by Application (2021-2025)
Table 65. Global Acute Intermittent Porphyria Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Acute Intermittent Porphyria Picture
Figure 2. Global Acute Intermittent Porphyria Revenue Market Share by Type in 2019
Figure 3. Gonadotropin-Releasing Hormone Analogues Picture
Figure 4. Prophylactic Hematin Infusions Picture
Figure 5. Acute Intermittent Porphyria Revenue Market Share by Application in 2019
Figure 6. Hospitals & Clinics Picture
Figure 7. Research Centers Picture
Figure 8. Global Acute Intermittent Porphyria Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Acute Intermittent Porphyria Revenue Share by Players in 2019
Figure 16. Global Top 5 Players Acute Intermittent Porphyria Revenue Market Share in 2019
Figure 17. Global Top 10 Players Acute Intermittent Porphyria Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global Acute Intermittent Porphyria Revenue Market Share by Regions (2015-2020)
Figure 21. Global Acute Intermittent Porphyria Revenue Market Share by Regions in 2018
Figure 22. North America Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 23. Europe Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 25. South America Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 27. North America Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Figure 28. North America Acute Intermittent Porphyria Revenue Market Share by Countries in 2019
Figure 29. USA Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 30. Canada Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 31. Mexico Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 32. Europe Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Figure 33. Europe Acute Intermittent Porphyria Revenue Market Share by Countries in 2019
Figure 34. Germany Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 35. UK Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 36. France Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 37. Russia Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 38. Italy Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific Acute Intermittent Porphyria Revenue Market Share by Countries in 2019
Figure 41. China Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 42. Japan Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 43. Korea Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 44. India Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 46. South America Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Figure 47. South America Acute Intermittent Porphyria Revenue Market Share by Countries in 2019
Figure 48. Brazil Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 49. Argentina Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa Acute Intermittent Porphyria Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa Acute Intermittent Porphyria Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 53. UAE Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 54. Egypt Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 55. South Africa Acute Intermittent Porphyria Revenue and Growth Rate (2015-2020)
Figure 56. Global Acute Intermittent Porphyria Revenue Share by Type (2015-2020)
Figure 57. Global Acute Intermittent Porphyria Revenue Share by Type in 2019
Figure 58. Global Acute Intermittent Porphyria Market Share Forecast by Type (2021-2025)
Figure 59. Global Gonadotropin-Releasing Hormone Analogues Revenue Growth Rate (2015-2020)
Figure 60. Global Prophylactic Hematin Infusions Revenue Growth Rate (2015-2020)
Figure 61. Global Acute Intermittent Porphyria Revenue Share by Application (2015-2020)
Figure 62. Global Acute Intermittent Porphyria Revenue Share by Application in 2019
Figure 63. Global Acute Intermittent Porphyria Market Share Forecast by Application (2021-2025)
Figure 64. Global Hospitals & Clinics Revenue Growth Rate (2015-2020)
Figure 65. Global Research Centers Revenue Growth Rate (2015-2020)
Figure 66. Global Acute Intermittent Porphyria Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global Acute Intermittent Porphyria Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global Acute Intermittent Porphyria Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
Figure 70. Europe Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
Figure 72. South America Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa Acute Intermittent Porphyria Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel

---